Novel CLDN18.2-TAC T cell candidate effectively eradicated Claudin 18.2-expressing gastric tumor cells in vitro and in vivo
AUSTIN, Texas, and HAMILTON, Ontario, November 13, 2021 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the company formed its inaugural Scientific Advisory Board (SAB), comprising four leading scientists and physicians. Jonathan Bramson, Ph.D., Scientific Co-Founder of Triumvira, Professor of Pathology and Molecular Medicine, and Vice Dean of Research at McMaster University, will serve as chair of the SAB.
